Daily Respiratory Research Analysis
Three advances shape today's respiratory research: hypoxia is shown to drive airway differentiation via HIF programs in human lung epithelium; the neutrophil-chemoattractant CXCL5 independently disrupts the alveolar epithelial barrier in acute lung injury; and applying updated PAH criteria identifies early portopulmonary hypertension in cirrhosis with markedly increased mortality. Together, these studies bridge mechanism to clinical risk stratification and therapeutic targeting.
Summary
Three advances shape today's respiratory research: hypoxia is shown to drive airway differentiation via HIF programs in human lung epithelium; the neutrophil-chemoattractant CXCL5 independently disrupts the alveolar epithelial barrier in acute lung injury; and applying updated PAH criteria identifies early portopulmonary hypertension in cirrhosis with markedly increased mortality. Together, these studies bridge mechanism to clinical risk stratification and therapeutic targeting.
Research Themes
- Hypoxia-driven epithelial plasticity in the human lung
- Chemokine-mediated barrier dysfunction in acute lung injury
- Early hemodynamic risk stratification in portopulmonary hypertension
Selected Articles
1. Hypoxia promotes airway differentiation in the human lung epithelium.
Using human tissue-derived organoids, the authors show that hypoxia drives airway differentiation and suppresses alveolar fate in human lung epithelium through HIF activity. HIF1α/HIF2α differentially regulate lineage decisions, with KLF4/KLF5 identified as direct HIF targets promoting basal and secretory cell fates. Hypoxia also converts fetal and adult AT2 cells into airway, including aberrant basal-like cells seen in fibrosis.
Impact: This study uncovers a direct, HIF-dependent mechanism by which hypoxia reprograms human lung epithelial fate, offering a unifying explanation for airway metaplasia in disease. It defines actionable transcriptional nodes (KLF4/KLF5) for future intervention.
Clinical Implications: Understanding hypoxia-HIF-driven epithelial plasticity suggests that modulating oxygenation or HIF signaling could mitigate maladaptive airway metaplasia in fibrotic or hypoxic lung diseases and guide regenerative strategies.
Key Findings
- Hypoxia promotes airway differentiation and suppresses alveolar differentiation in human lung epithelial organoids.
- Airway fate under hypoxia requires HIF activity; HIF1α and HIF2α differentially regulate lineage choices.
- KLF4 and KLF5 are direct HIF targets that promote basal and secretory cell fates.
- Hypoxia converts fetal and adult AT2 cells to airway lineages, including aberrant basal-like cells seen in fibrotic lungs.
Methodological Strengths
- Use of human tissue-derived organoids spanning fetal and adult AT2 cells with chemical and genetic HIF perturbations
- Mechanistic mapping of HIF1α/HIF2α with identification of direct downstream effectors (KLF4/KLF5)
Limitations
- Findings are largely from in vitro organoid systems without in vivo human interventional validation
- Clinical contexts and thresholds of hypoxia that trigger reprogramming remain to be defined
Future Directions: Define hypoxia thresholds and microenvironmental cues in diseased lungs that elicit HIF-driven metaplasia; test pharmacologic HIF modulation to prevent aberrant airway conversion in fibrosis models.
Human lungs experience dynamic oxygen tension during development. Here, we show that hypoxia directly regulates human lung epithelial cell identity using tissue-derived organoids. Fetal multipotent lung epithelial progenitors remain undifferentiated in a self-renewing culture condition under normoxia but spontaneously differentiate toward multiple airway cell types and inhibit alveolar differentiation under hypoxia. Using chemical and genetic tools, we demonstrate that hypoxia-induced airway differentiation depends on hypoxia-induc
2. Neutrophil-chemoattractant CXCL5 increases lung barrier permeability in acute lung injury.
CXCL5 is induced by pneumococcal pneumonia and mechanical ventilation and directly compromises alveolar epithelial barrier integrity. Cxcl5-deficient mice retain barrier function despite acute lung injury, independent of neutrophil recruitment, corroborated by scRNA-seq showing enhanced junctional programs and by CXCL5-induced barrier disruption in TNF-primed human alveolar epithelial cells. Targeting CXCL5 could preserve barrier function in severe pneumonia.
Impact: Reveals a neutrophil-independent, barrier-disruptive function of a canonical chemokine, reframing CXCL5 as a direct effector of epithelial permeability and a therapeutic target in pneumonia-associated lung injury.
Clinical Implications: Adjunctive CXCL5 inhibition with antibiotics may reduce barrier leak and inflammation in severe bacterial pneumonia, potentially improving oxygenation and outcomes.
Key Findings
- Pneumococcal infection and mechanical ventilation trigger CXCL5 release in humans and mice.
- Cxcl5-deficient mice maintain alveolar-epithelial barrier integrity during acute lung injury, independent of neutrophil recruitment.
- Single-cell transcriptomics show enhanced epithelial junctional transcripts in Cxcl5-deficient lungs.
- CXCL5 exposure disrupts barrier function of TNF-primed human primary alveolar epithelial cells.
Methodological Strengths
- Translational approach integrating patient data, mouse knockouts, and primary human epithelial cell assays
- Use of single-cell transcriptomics to mechanistically link CXCL5 to epithelial junctional programs
Limitations
- Clinical sample size and heterogeneity are not detailed, limiting direct generalizability
- Therapeutic CXCL5 blockade was not tested in patients; off-target effects and timing require evaluation
Future Directions: Evaluate pharmacologic CXCL5 blockade in preclinical pneumonia models alongside antibiotics; define patient endotypes with CXCL5-high signatures for targeted trials.
Acute lung injury is a common complication of pneumonia, with disease severity linked to inflammatory cell recruitment and lung barrier dysfunction. In this study, we investigate the role of neutrophil-chemoattractant CXCL5 in lung barrier function and inflammation. We examined CXCL5 in patients with severe pneumonia and in in vitro and in vivo models of acute lung injury. Pneumococcal infection and mechanical ventilation triggered CXCL5 release in both humans and mice. In Cxcl5-deficient mice, the alveolar-ep
3. Early portopulmonary hypertension predicts mortality in patients with cirrhosis: Insights from the PORTO-DETECT cohort.
In a multicenter RHC-confirmed cohort of 428 cirrhotic patients, early PoPH defined by 2022 ESC/ERS criteria was associated with a 3.5-fold higher mortality risk versus normal hemodynamics, with 3-year survival of 49.5%. Associations remained after adjustment and in competing-risk models. Findings support systematic screening and earlier consideration of targeted therapies.
Impact: Demonstrates that newly defined early PoPH carries substantial mortality risk independent of liver disease severity, directly informing screening thresholds and clinical pathways.
Clinical Implications: Adopt updated ESC/ERS criteria to screen cirrhotic patients for early PoPH via echocardiography and confirmatory RHC; consider earlier referral and targeted PAH therapy evaluation in selected patients.
Key Findings
- Early PoPH (mPAP 20.5–24.5 mmHg, PVR >2 WU) had a 3-year survival of 49.5% versus 76.7% in normal hemodynamics.
- Adjusted hazard ratio for mortality was 3.5 for early PoPH and 4.5 for classic PoPH vs normal; results held in competing-risk models.
- Post-capillary PH and unclassified hemodynamic profiles did not differ from normal in mortality risk.
Methodological Strengths
- Multicenter cohort with invasive hemodynamic confirmation by right-heart catheterization
- Robust statistical adjustment and competing-risk analyses accounting for liver transplantation
Limitations
- Observational design limits causal inference and may be affected by residual confounding
- Selection bias possible as all participants underwent RHC in specialized centers
Future Directions: Prospective screening studies in broader cirrhotic populations; interventional trials testing early targeted PAH therapies in early PoPH.
BACKGROUND & AIMS: Portopulmonary hypertension (PoPH) is a severe complication of cirrhosis and portal hypertension. In 2022, a European task force revised the diagnostic criteria for pulmonary arterial hypertension (PAH), defining early stages as a mean pulmonary arterial pressure (mPAP) of 20.5-24.5 mmHg and pulmonary vascular resistance (PVR) >2 Wood units. We evaluated the prognostic value of these revised criteria in patients with cirrhosis. METHODS: In this longitudinal, multicenter, observational cohort, 428 adults with cirrhosis and portal hypertension underwent right-heart catheterization between 2015 and 2023 and were stratified into five groups: normal, early PoPH, classic PoPH, post-capillary pulmonary hypertension, and unclassified profiles. All-cause mortality was analyzed by multivariable Cox regression and competing-risk models, with liver transplantation as an intercurrent event. RESULTS: Over a median follow-up time of 20.0 months (IQR 8.0-36.0), 3-year survival rates were 76.7%, 49.5%, and 42.0% in the normal mPAP, early PoPH, and classic PoPH groups, respectively. After adjustment for age, sex, liver function, and portal hypertension severity, both early PoPH (hazard ratio 3.5; 95% CI 1.9-6.3; p <0.01) and classic PoPH (hazard ratio 4.5; 2.6-7.6; p <0.01) remained independent predictors of mortality vs. normal mPAP; these associations persisted in competing-risk analysis, whereas post-capillary pulmonary hypertension and unclassified groups did not differ from the normal mPAP cohort. CONCLUSION: Applying the 2022 ESC/ERC definitions of PAH identifies a subset of patients with cirrhosis with early-stage PoPH, characterized by mild pulmonary vascular resistance elevation, who nevertheless face a markedly increased risk of death, emphasizing the need for systematic screening and early targeted intervention. IMPACT AND IMPLICATIONS: Portopulmonary hypertension (PoPH) is a severe and often overlooked complication of cirrhosis. Using the updated 2022 ESC/ERS diagnostic criteria, this multicenter study identified a previously unrecognized subgroup of patients with cirrhosis and early-stage PoPH, defined by mildly elevated pulmonary vascular resistance and mean pulmonary artery pressure. Despite their subtle hemodynamic changes, these patients showed significantly reduced survival, independent of liver disease severity. These results highlight the prognostic relevance of early PoPH and suggest that applying the new criteria may help refine risk stratification and guide closer follow-up or earlier consideration of targeted interventions in selected patients.